Description
The purpose of this NIH-funded placebo-controlled clinical trial is to determine how well ferric citrate will lower FGF23, correct anemia and iron levels in the blood, and maintain normal levels of phosphate in children with CKD. Chronic Kidney Disease (CKD) is a condition in which the kidney function is decreased. Fibroblast Growth Factor 23 (FGF23) is a hormone that regulates blood phosphate levels. High FGF23 levels are linked with worsening of kidney, bone & heart health. Ferric Citrate is an oral medication that decreases the absorption of dietary phosphate by the gut, lowers FGF23 levels and raises iron stores in the body. Ferric Citrate is approved in adults with CKD but has not yet been studied in children.
For more information visit www.fit4kidstudy.com
What to expect
Eligible participants will be randomized to take ferric citrate or placebo with meals for about one year.The study will include 6 in-person study visits, 3 virtual visits and 6 telephone calls. Participants will be asked to give blood and urine samples, and to complete surveys.
